Evidence map›Paper›PMID 26020725›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2015

The Tpl2 Kinase Regulates the COX-2/Prostaglandin E2 Axis in Adipocytes in Inflammatory Conditions.

Flavien Berthou, Franck Ceppo, Karine Dumas, Fabienne Massa, Bastien Vergoni, Susana Alemany, Mireille Cormont, Jean-François Tanti

Open access · bronzeAbstract read
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. PGECell communication and signaling : CCS · 2022
    Article
  2. Article
  3. Article
  4. Review
  5. Antiarthritic Activity ofOpen access Macedonian journal of medical sciences · 2019
    Article
  6. Cyclooxygenase-2 in Endometriosis.International journal of biological sciences · 2019
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Flavien BerthouInserm (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Unit 1065, Centre Méditerranéen de Médecine Moléculaire, Team 7 "Molecular and Cellular Physiopathology of Obesity and Diabetes," and Université Nice Sophia Antipolis (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Centre Méditerranéen de Médecine Moléculaire, 06204 Cedex 3 Nice, France; and Instituto Investigaciones Biomédicas Alberto Sols (S.A.), Consejo Superior de Investigaciones Científicas-Universidad Autonoma de Madrid, 28029 Madrid, Spain.
Franck CeppoInserm (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Unit 1065, Centre Méditerranéen de Médecine Moléculaire, Team 7 "Molecular and Cellular Physiopathology of Obesity and Diabetes," and Université Nice Sophia Antipolis (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Centre Méditerranéen de Médecine Moléculaire, 06204 Cedex 3 Nice, France; and Instituto Investigaciones Biomédicas Alberto Sols (S.A.), Consejo Superior de Investigaciones Científicas-Universidad Autonoma de Madrid, 28029 Madrid, Spain.
Karine DumasInserm (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Unit 1065, Centre Méditerranéen de Médecine Moléculaire, Team 7 "Molecular and Cellular Physiopathology of Obesity and Diabetes," and Université Nice Sophia Antipolis (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Centre Méditerranéen de Médecine Moléculaire, 06204 Cedex 3 Nice, France; and Instituto Investigaciones Biomédicas Alberto Sols (S.A.), Consejo Superior de Investigaciones Científicas-Universidad Autonoma de Madrid, 28029 Madrid, Spain.
Fabienne MassaInserm (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Unit 1065, Centre Méditerranéen de Médecine Moléculaire, Team 7 "Molecular and Cellular Physiopathology of Obesity and Diabetes," and Université Nice Sophia Antipolis (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Centre Méditerranéen de Médecine Moléculaire, 06204 Cedex 3 Nice, France; and Instituto Investigaciones Biomédicas Alberto Sols (S.A.), Consejo Superior de Investigaciones Científicas-Universidad Autonoma de Madrid, 28029 Madrid, Spain.
Bastien VergoniInserm (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Unit 1065, Centre Méditerranéen de Médecine Moléculaire, Team 7 "Molecular and Cellular Physiopathology of Obesity and Diabetes," and Université Nice Sophia Antipolis (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Centre Méditerranéen de Médecine Moléculaire, 06204 Cedex 3 Nice, France; and Instituto Investigaciones Biomédicas Alberto Sols (S.A.), Consejo Superior de Investigaciones Científicas-Universidad Autonoma de Madrid, 28029 Madrid, Spain.
Susana AlemanyInserm (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Unit 1065, Centre Méditerranéen de Médecine Moléculaire, Team 7 "Molecular and Cellular Physiopathology of Obesity and Diabetes," and Université Nice Sophia Antipolis (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Centre Méditerranéen de Médecine Moléculaire, 06204 Cedex 3 Nice, France; and Instituto Investigaciones Biomédicas Alberto Sols (S.A.), Consejo Superior de Investigaciones Científicas-Universidad Autonoma de Madrid, 28029 Madrid, Spain.
Mireille CormontInserm (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Unit 1065, Centre Méditerranéen de Médecine Moléculaire, Team 7 "Molecular and Cellular Physiopathology of Obesity and Diabetes," and Université Nice Sophia Antipolis (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Centre Méditerranéen de Médecine Moléculaire, 06204 Cedex 3 Nice, France; and Instituto Investigaciones Biomédicas Alberto Sols (S.A.), Consejo Superior de Investigaciones Científicas-Universidad Autonoma de Madrid, 28029 Madrid, Spain.
Jean-François TantiInserm (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Unit 1065, Centre Méditerranéen de Médecine Moléculaire, Team 7 "Molecular and Cellular Physiopathology of Obesity and Diabetes," and Université Nice Sophia Antipolis (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Centre Méditerranéen de Médecine Moléculaire, 06204 Cedex 3 Nice, France; and Instituto Investigaciones Biomédicas Alberto Sols (S.A.), Consejo Superior de Investigaciones Científicas-Universidad Autonoma de Madrid, 28029 Madrid, Spain.
Inserm · FRCentre Méditerranéen de Médecine Moléculaire · FRConsejo Superior de Investigaciones Científicas · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bioactive lipid mediators such as prostaglandin E2 (PGE2) have emerged as potent regulator of obese adipocyte inflammation and functions. PGE2 is produced by cyclooxygenases (COXs) from arachidonic acid, but inflammatory signaling pathways controlling COX-2 expression and PGE2 production in adipocytes remain ill-defined. Here, we demonstrated that the MAP kinase kinase kinase tumor progression locus 2 (Tpl2) controls COX-2 expression and PGE2 secretion in adipocytes in response to different inflammatory mediators. We found that pharmacological- or small interfering RNA-mediated Tpl2 inhibition in 3T3-L1 adipocytes decreased by 50% COX-2 induction in response to IL-1β, TNF-α, or a mix of the 2 cytokines. PGE2 secretion induced by the cytokine mix was also markedly blunted. At the molecular level, nuclear factor κB was required for Tpl2-induced COX-2 expression in response to IL-1β but was inhibitory for the TNF-α or cytokine mix response. In a coculture between adipocytes and macrophages, COX-2 was mainly increased in adipocytes and pharmacological inhibition of Tpl2 or its silencing in adipocytes markedly reduced COX-2 expression and PGE2 secretion. Further, Tpl2 inhibition in adipocytes reduces by 60% COX-2 expression induced by a conditioned medium from lipopolysaccharide (LPS)-treated macrophages. Importantly, LPS was less efficient to induce COX-2 mRNA in adipose tissue explants of Tpl2 null mice compared with wild-type and Tpl2 null mice displayed low COX-2 mRNA induction in adipose tissue in response to LPS injection. Collectively, these data established that activation of Tpl2 by inflammatory stimuli in adipocytes and adipose tissue contributes to increase COX-2 expression and production of PGE2 that could participate in the modulation of adipose tissue inflammation during obesity.

Indexed as

Signal Transduction3T3-L1 CellsAdipocytesAnimalsArachidonate 5-LipoxygenaseCaspase 3Coculture TechniquesCulture Media, ConditionedCyclic AMP Response Element-Binding ProteinCyclooxygenase 2CytokinesDinoprostoneInflammationInflammation MediatorsInterleukin-1betaLipopolysaccharidesArachidonate 5-LipoxygenaseCaspase 3Culture Media, ConditionedCyclic AMP Response Element-Binding ProteinCyclooxygenase 2CytokinesDinoprostoneInflammation MediatorsInterleukin-1betaLipopolysaccharidesMap3k8 protein, mouseMAP Kinase Kinase KinasesNF-kappa BProtein Kinase InhibitorsProto-Oncogene ProteinsRNA, MessengerTumor Necrosis Factor-alpha

Identifiers

PMID26020725
PMCPMC5414708
OpenAlexW2179432351

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.